Aligos Therapeutics vs Taysha Gene Therapies
ALGS and TSHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALGS and TSHA compare
Taysha Gene Therapies is the larger company, worth 52 times as much as Aligos Therapeutics ($1.4B against $27.0M).
Aligos Therapeutics grew revenue faster over the last twelve months (122% versus −13.1% for Taysha Gene Therapies).
Aligos Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1137% compared with −2845% at Taysha Gene Therapies.
Aligos Therapeutics scores higher on the StockData Score (7 against 5 for Taysha Gene Therapies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALGS | TSHA |
|---|---|---|
| Size and price | ||
| Market cap | $27.0M | $1.4B |
| Share price | $2.16 | $4.28 |
| Change, 1 year | −68.6% | 10.0% |
| Change, 5 years | −99.5% | −68.3% |
| Beta (5Y) | 1.51 | 2.11 |
| Employees | 82 | 99 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.6× (better) | 254× |
| P/B | 2.4× (better) | 3.9× |
| FCF yield | – | −10.2% |
| Fair value | $2.40 | – |
| Margin of safety | 9.8% | – |
| Growth | ||
| Revenue growth (TTM) | 122% (better) | −13.1% |
| Profitability | ||
| Operating margin | −1244% (better) | −2935% |
| Net margin | −1137% (better) | −2845% |
| FCF margin | – | −2583% |
| Return on equity | −159% | −54.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.13 (better) |
| Interest coverage | – | −5193.8× |
| Current ratio | 1.77 | 18.56 (better) |
| Altman Z-score | −24.54 | 7.92 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 18.4% | 91.9% |
| Held by insiders | – | 10.7% |
| Insider net buying, 12 months | – | −$6.1M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 18.4% |
Go deeper
- ALGS stock overview
- ALGS income statement
- ALGS valuation and score
- TSHA stock overview
- TSHA income statement
- TSHA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.